
    
      Utilizing the ABC/3TC FDC tablets as the NRTI backbone, this open label study will compare
      the safety and efficacy of ABC/3TC when used as replacement for subjects with suboptimal CD4-
      cells count who are receiving TDF/FTC. TYhis study will be conducted for 48 weeks in HIV
      infected, HLA*B5701 begative subjects who were initially suppressed on a HAART regiment that
      includes TDF/FTC QD.
    
  